IDEAYA Biosciences vs Puma Biotechnology
IDYA and PBYI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IDYA and PBYI compare
IDEAYA Biosciences is the larger company, worth 7.7 times as much as Puma Biotechnology ($3.1B against $401M).
Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 10.3% compared with −74.8% at IDEAYA Biosciences.
Puma Biotechnology scores higher on the StockData Score (14 against 9 for IDEAYA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IDYA | PBYI |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $401M |
| Share price | $31.83 | $7.77 |
| Change, 1 year | −0.38% | 55.7% |
| Change, 5 years | 37.1% | 127% |
| Beta (5Y) | 0.78 | 0.97 |
| Employees | 145 | 179 |
| StockData Score | ||
| Total score | 9 | 14 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 16.9× |
| P/S | 13.1× | 1.7× (better) |
| P/B | 2.6× (better) | 2.7× |
| EV/EBITDA | – | 8.3× |
| P/FCF | – | 8.7× |
| FCF yield | −3.7% | 11.5% (better) |
| Fair value | $29.10 | $8.76 |
| Margin of safety | −9.4% | 11.3% (better) |
| Growth | ||
| Revenue growth (TTM) | – | 9.4% |
| Revenue growth, 5Y average | 62.1% (better) | 0.29% |
| Net income growth (TTM) | – | −35.6% |
| EPS growth (TTM) | – | −37.8% |
| Profitability | ||
| Gross margin | – | 73.6% |
| Operating margin | −92.7% | 11.3% (better) |
| Net margin | −74.8% | 10.3% (better) |
| FCF margin | −48.6% | 19.9% (better) |
| Return on equity | −16.2% | 18.2% (better) |
| Return on invested capital | −51.9% | 38.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Net debt / EBITDA | – | −2.77 |
| Interest coverage | – | 12.9× |
| Current ratio | 10.45 (better) | 3.03 |
| Altman Z-score | 15.97 (better) | −2.31 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 106% | 74.9% |
| Held by insiders | 0.83% | 18.9% |
| Insider net buying, 12 months | $281K (better) | −$2.0M |
| Short interest, % of float | 8.6% | 10.3% |
Go deeper
- IDYA stock overview
- IDYA income statement
- IDYA valuation and score
- PBYI stock overview
- PBYI income statement
- PBYI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.